Auna S.A. (AUNA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance, especially in Mexico and Peru, with promising growth projections. The partnership with Sojitz and debt refinancing are positive catalysts. The Q&A highlights confidence in guidance despite some macroeconomic risks, and the potential for share buybacks suggests shareholder returns. However, lack of specific guidance details and high impairment losses in Peru are concerns. Overall, the positive aspects outweigh the negatives, suggesting a positive stock price reaction.
Key Financial Performance
Consolidated adjusted net income PEN 136 million in the quarter compared with PEN 36 million in the same quarter last year, more than tripling to PEN 336 million for the full year. This was supported by strong free cash flow generation and a 42% increase in cash position.
Consolidated revenue Grew 6% FX neutral in the quarter and 4% for the full year. This growth was driven by Peru's strong performance and Colombia's resilience, which offset setbacks in Mexico.
Adjusted EBITDA Declined 14% FX neutral in the quarter and 3% for the full year. The decline was mainly due to Mexico's underperformance and unfavorable year-over-year comparisons in Colombia.
Capacity utilization in healthcare services Decreased 2.3 percentage points to 64%, reflecting lower utilization, particularly in Colombia, as part of a focus to reduce reliance on intervened payors.
Oncosalud Peru planned memberships Increased 4.4%, with the oncology MLR improving to a record low of 48.5%.
Mexico Oncology revenues Grew 35% compared with the previous quarter, with Out-of-Pocket revenues increasing to 12% of total revenues in December, up from 8% in the third quarter.
Mexico fourth quarter revenues Declined 3% in local currency due to soft market conditions, lower surgeries, and emergency visits. However, revenues were unchanged from the previous quarter, reflecting stabilization.
Mexico fourth quarter adjusted EBITDA Declined 36% and was down 18% for the full year, due to lower revenues and profitability, as well as higher costs and lower margins under the previous healthcare plan with ISSSTELEON.
Peru revenue Increased 11% during the quarter, driven by growth in high complexity services, higher volumes, and annual price adjustments.
Peru adjusted EBITDA Increased 14% in the quarter and for the full year, supported by operational scale and targeted marketing initiatives.
Colombia revenue Increased 6% in the quarter and 4% for the full year, driven by higher tickets, surgeries, and emergency treatments, despite lower volumes.
Colombia adjusted EBITDA Declined due to unfavorable year-over-year comparisons with extraordinary price adjustments and procurement rebates in the prior year.
Free cash flow Grew 35% to PEN 582 million, with a year-end cash position increasing 42% to PEN 335 million, supported by improved cash conversion and reduced interest expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Oncology revenues in Mexico: Grew 35% in the fourth quarter compared to the previous quarter, driven by the integration of Opcion Oncologia and the launch of the new Oncocenter at Doctors Hospital.
Centro Ambulatorio Trecca in Peru: Signed an agreement to refurbish and operate a 600,000 square foot high complexity outpatient facility in Lima, expanding access to care for approximately 3 million patients.
Mexico market recovery: Stabilized operations with initiatives to expand reach into privately insured families and alignment with physician groups. Included in policies serving larger segments of the privately insured market.
Peru market growth: Strong performance driven by high complexity services, increased bed capacity, and targeted marketing initiatives. Revenue increased 11% in the quarter.
Colombia market resilience: Revenue increased 6% in the quarter, supported by higher tickets and surgeries, and expansion of risk-sharing models like PGP.
Debt refinancing: Completed $825 million debt refinancing, improving maturity profile, lowering interest expenses, and increasing cash position by 42%.
Operational turnaround in Mexico: Implemented new leadership and initiatives to improve physician engagement, productivity, and clinical outcomes. Out-of-Pocket revenues increased to 12% of total revenues in December.
Strategic growth in Mexico: Focused on regaining volumes and margins through inclusion in preferred provider tiers, packaged services, and agreements with insurers to direct policyholders to Auna's oncology services.
Risk mitigation in Colombia: Diversified away from intervened payors and prioritized cash flows through PGP arrangements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Mexico Operations: Disappointing results for the year due to volume losses earlier in 2025. Market conditions remained soft, affecting surgeries and emergency visits. Legacy volume and margin pressures related to physician and supplier relationships persist. Higher costs and lower margins under the previous healthcare plan with ISSSTELEON impacted profitability.
Colombia Operations: Reliance on intervened payors posed risks to accounts receivables and cash cycle. Extraordinary pricing adjustments in 2024 created unfavorable year-over-year comparisons. Higher proportion of risk-sharing contracts impacted EBITDA.
Debt Refinancing: $825 million debt refinancing incurred premiums and costs, impacting financials. Extraordinary refinancing expenses affected net interest expenses and effective tax rate.
Economic and Market Conditions: Soft demand in Mexico and unfavorable market conditions contributed to revenue declines. Economic uncertainties in Colombia necessitated risk mitigation measures.
Strategic Execution Risks: Turnaround efforts in Mexico are ongoing, with risks tied to execution of new leadership strategies and operational adjustments. Dependence on new initiatives like ISSSTELEON healthcare plan and PGP arrangements in Colombia to drive growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Projected revenue growth of 12% for 2026, driven by sustained commercial momentum and operational execution.
Adjusted EBITDA: Expected to increase by 12% FX-neutral in 2026, supported by disciplined cost management and ongoing investments in strategic growth initiatives.
Capital Expenditures (CapEx): CapEx is expected to remain at approximately 4% of revenue, balancing growth investments with cash flow generation.
Mexico Operations: Mexico is expected to recover in 2026, regaining volumes and margins. Initiatives include increased accessibility to policyholders and coverage plans, partnerships with private insurance companies, employer groups, and ISSSTELEON.
Peru Operations: Continued growth expected, supported by initiatives such as Centro Ambulatorio Trecca, which will expand the addressable market. Peru remains a key driver of growth.
Colombia Operations: Focus on diversifying away from intervened payors and prioritizing cash flows through PGP arrangements.
Debt Structure and Financial Flexibility: Strengthened capital structure with a target leverage ratio of 3x net debt-to-EBITDA in the medium term, enabling execution of growth strategy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you break down your guidance by region or business line, and explain the growth and EBITDA expansion in each line?
A:Management highlighted Mexico's recovery as a key driver of improvement, with single-digit growth in surgery, double-digit growth in radiotherapy and chemotherapy, and occupancy utilization reaching 41%. They expect higher volumes and margin gains in 2026 due to cost containment strategies and the expansion of ISSSTELEON. However, they did not provide specific guidance by country.
Q:What are the risks to your 2026 guidance?
A:Management identified potential risks such as macroeconomic conditions, payer dynamics, and the pace of volume recovery in Mexico. However, they expressed confidence in achieving the guidance due to stability in Mexico and strong performance in Peru.
Q:Can you provide more details on Torre Trecca, including margins, revenue contribution, and opening date?
A:Torre Trecca, now called Centro Ambulatorio Trecca, is an ambulatory center in Peru expected to commence operations in the second half of 2028. It will provide 3 million services for EsSalud and is projected to represent 20-25% of Auna's business in Peru at maturity. The project is structured under a concession framework with predictable revenues and minimal capital risk.
Q:What is the expected CapEx for 2026 and beyond?
A:The 2026 CapEx is approximately 4% of revenue, allocated to maintenance, medical equipment, infrastructure, and technology investments. Management did not provide specific guidance for 2027 or 2028 but mentioned potential investments for expanding the Lima network.
Q:When do you expect Mexico's total occupancy rate to reach 40%?
A:Management stated that Mexico's occupancy rate has already reached 41% and continues to show potential for growth throughout the year.
Q:What conditions are required for provisions to be reversed in Colombia? Could this happen in the first half of 2026?
A:Provisions in Colombia are based on an expected loss model, and management does not expect any reversals in the first half of 2026.
Q:Can you provide an update on the Sojitz MOU?
A:Discussions with Sojitz are ongoing, focusing on potential capital increases to support growth in Mexico. Management is not ready to provide specific updates but emphasized the importance of inorganic growth.
Q:What is the all-in cost of debt after refinancing?
A:The blended rate dropped by over 100 basis points to approximately 11.5%, with 56% of debt in local currency and 44% in U.S. dollars (85% hedged to Peruvian sol).
Q:How is the Board prioritizing capital allocation given the positive free cash flow?
A:The Board is considering various options, including share buybacks, but prioritizes using the balance sheet to support growth in Mexico, particularly in high-complexity, higher-margin opportunities.
Q:How are you planning the ramp-up in occupancy in Mexico and margin recovery to 30%?
A:Management plans to manage occupancy and margins through a mix of higher-complexity services and cost containment strategies. They aim to recover a couple of margin points in 2026.
Q:How did ISSSTE impact performance in Mexico in Q4, and how will the extension improve 2026?
A:The 2025 ISSSTE contract had lower margins due to higher complexity volume. The 2026 extension includes a 30% price increase and better cost control, expected to improve margins.
Q:Why were there high impairment losses in trade receivables in Peru?
A:Impairment losses in Peru were due to specific conciliation issues with payers from previous years, related to services in 2024. Management expects no further increases in impairments in 2026.
Q:How much of Peru's performance is structural versus temporary?
A:Management views Peru's performance as stable and predictable, driven by a mature model and integrated insurance business. They do not attribute the performance to temporary or unusual factors.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance by country or business line, despite being asked for a detailed breakdown. They also did not disclose specific CapEx figures for 2027 and 2028, and refrained from providing updates on the Sojitz MOU or detailed financial projections for Torre Trecca.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EsSalud
FX PEN
ISSSTELEON security
Mexico underperformance
Monterrey
Oncocenter
PEN decrease
PEN margin
PEN noncash
Peru scale
basis service
bridge
comparison
decrease PEN
employee state
extension healthcare
healthcare plan
income PEN
income tax
institution state
interest expense
investment
item
net
plan ISSSTELEON
policy segment
premium refinancing
productivity outcome
recovery
reliance payors
result Mexico
security institution
service ISSSTELEON
side slide
sol
structure
turnaround Mexico
volume margin
AUNA Transcript
Auna S.A. (AUNA) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call summary indicates strong financial performance, especially in Mexico and Peru, with promising growth projections. The partnership with Sojitz and debt refinancing are positive catalysts. The Q&A highlights confidence in guidance despite some macroeconomic risks, and the potential for share buybacks suggests shareholder returns. However, lack of specific guidance details and high impairment losses in Peru are concerns. Overall, the positive aspects outweigh the negatives, suggesting a positive stock price reaction.
Auna S.A. (AUNA) Q3 2025 Earnings Call Transcript
Positive11-21
The earnings call summary highlights strong growth in Peru and Colombia, strategic partnerships like the one with Sojitz, and expansion plans in Mexico. Despite some concerns about Mexico's revenue decline and system integration delays, the positive outlook on market recovery, margin improvements, and strategic investments suggest a positive sentiment. The Q&A section reinforced this with optimism about growth opportunities, despite some uncertainties in guidance. Overall, the positive aspects, especially the Sojitz partnership and expansion plans, outweigh the negatives, indicating a likely positive stock price reaction.
Auna S.A. (AUNA) Q2 2025 Earnings Call Transcript
Unknown8-20
The earnings call presents a mixed picture. Positive aspects include revenue growth in Mexico and OncoSalud, improved EBITDA in Colombia, and strong adjusted net income. However, concerns include flat revenue in Colombia, decreasing cash position, and vague management responses about growth in Mexico. The Q&A revealed optimism about margin maintenance and risk-sharing in Colombia, but also highlighted ongoing challenges in Mexico. Given these mixed signals and lack of a market cap, a neutral stock price movement is expected.
Earnings call transcript: Auna SAA ADR Q4 2024 misses EPS forecast, stock dips
Unknown3-11
The earnings call presents mixed signals: strong financial performance with revenue and EBITDA growth, but challenges in Colombia and lack of clear guidance. The Q&A reveals management's cautious stance and reluctance to provide specific forecasts, adding uncertainty. Despite positive financials, the strategic focus on cash flow over growth suggests limited short-term upside. The absence of a shareholder return plan and operational risks in Colombia further temper expectations. Overall, these factors balance out, leading to a neutral stock price prediction.
AUNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
